AmadorXF, StraussDH: The Scale to Assess Unawareness of Mental Disorder (SUMD). New York: New York State Psychiatric Institute, Columbia University; 1990.
2.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
3.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
4.
FazeliPK, CalderGL, MillerKK, MisraM, LawsonEA, MeenaghanE, LeeH, HerzogD, KlibanskiA: Psychotropic medication use in anorexia nervosa between 1997 and 2009. Int J Eat Disord, 45:970–976, 2012.
5.
HagmanJ, GrallaJ, SigelE, EllertS, DodgeM, GardnerR, O'LonerganT, FrankG, WamboldtMZ: A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: A pilot study. J Am Acad Child Adolesc Psychiatry, 50:915–924, 2011.
6.
KafantarisV, LeighE, HertzS, BerestA, SchebendachJ, SterlingWM, SaitoE, SundayS, HigdonC, GoldenNH, MalhotraAK: A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol, 21:207–212, 2011.
7.
KaufmanJ, BirmaherB, BrentD, RaoU, FlynnC, MoreciP, WilliamsonD, RyanN: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry, 36:980–988, 1997.
8.
KishiT, KafantarisV, SundayS, SheridanEM, CorrellCU: Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry, 73:e757–766, 2012.
9.
LebowJ, SimLA, ErwinPJ, MuradMH: The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord, 46:332–339, 2013.
10.
LeggeroC, MasiG, BrunoriE, CalderoniS, CarissimoR, MaestroS, MuratoriF: Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: Focus on hyperactivity. J Child Adolesc Psychopharmacol, 20:127–133, 2010.
11.
McElroySL, FryeMA, HellemannG, AltshulerL, LeverichGS, SuppesT, KeckPE, NolenWA, KupkaR, PostRM: Prevalence and correlates of eating disorders in 875 patients with bipolar disorder. J Affect Disord, 128:191–198, 2011.
12.
National Institute of MentalHealth: Clinical Global Impressions Scale. Psychopharmacol Bull, 21:839–843, 1985.
13.
NorrisML, SpettigueW, BuchholzA, HendersonKA, GomezR, MarasD, GabouryI, NiA: Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol, 21:213–220, 2011.
14.
NorrisML, SpettigueW, BuchholzA, HendersonKA, ObeidN: Factors influencing research drug trials in adolescents with anorexia nervosa. Eat Disord, 18:210–217, 2010.
15.
ShafferD, GouldMS, BrasicJ, AmbrosiniP, FisherP, BirdH, AluwahliaSA: Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry, 40:1228–1231, 1983.
16.
SwenneI, RoslingA: No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders. J Child Adolesc Psychopharmacol., 21:221–227, 2011.
